Press Releases

Press Releases

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12

NEW YORK, NY – JANUARY 7, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. EST. Investors, analysts, members of the media and the general public are invited to

Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities

NEW YORK, NY, December 22, 2020 – Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller University, Mount Sinai Health System and Columbia University. This amount includes donations from Royalty

Royalty Pharma Donates $1,000,000 to Support Mount Sinai’s Covid-19 Patient Care and Clinical Research

NEW YORK, NY, December 21, 2020 – Royalty Pharma (Nasdaq: RPRX) today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System. The funds will be used to support: Mount Sinai’s Center for Post-COVID Care (CPCC) and Post-COVID Registry:   Royalty

Royalty Pharma Announces Expansion of Leadership Team

NEW YORK , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team: Jim Reddoch , PhD will assume increased responsibilities with a new role of Chief Scientific Officer, which is in addition to his position as Co-Head of Research &

Royalty Pharma and Pablo and Almudena Legorreta Support Development of Antibody Based Covid-19 Therapy at The Rockefeller University

NEW YORK, NY, December 17, 2020 – Royalty Pharma (Nasdaq: RPRX) and The Rockefeller University announced generous gifts totaling $5,760,000 from Royalty Pharma and Pablo and Almudena Legorreta. Half of the gift will be donated by Royalty Pharma and the other half by Pablo and Almudena Legorreta

Royalty Pharma Acquires Royalty Interest In Orladeyo and BCX9930 from Biocryst Pharmaceuticals

NEW YORK, NY and RESEARCH TRIANGLE PARK, N.C, December 7, 2020 – Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to

Royalty Pharma Reports Third Quarter 2020 Results

Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts Increased 2020 guidance: Adjusted Cash Receipts expected to be $1,780 to $1,800 million $2.3 billion of new acquisitions announced in 2020, including $1.1 billion in the third quarter

Royalty Pharma Acquires Additional Royalty Interest from the Cystic Fibrosis Foundation

NEW YORK, NY, November 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575

Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders

NEW YORK , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per

Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020

NEW YORK , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00
Displaying 41 - 50 of 98